Compare Inovio Pharmaceuticals Inc (INO) vs State Street Real Estate Select Sector SPDR ETF (XLRE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Inovio Pharmaceuticals Inc vs State Street Real Estate Select Sector SPDR ETF — how do they compare? Inovio Pharmaceuticals Inc trades at $1.15 (market cap $112.19M), while State Street Real Estate Select Sector SPDR ETF trades at $41.61 (market cap $7.61B). The key difference: State Street Real Estate Select Sector SPDR ETF is far larger — about 67.8× Inovio Pharmaceuticals Inc's market cap, and State Street Real Estate Select Sector SPDR ETF is more actively traded (7,876,569 versus 3,201,278). Which is the better fit depends on your goals — on Pluang, investors hold Inovio Pharmaceuticals Inc for 43 Days and State Street Real Estate Select Sector SPDR ETF for 75 Days on average.
| INO | XLRE | |
|---|---|---|
Market Cap | $112.19M | $7.61B |
Volume | 3,201,278 | 7,876,569 |
Sector | Health | Sector/Thematic |
52-Week High | $2.65 | $46.01 |
52-Week Low | $0.66 | $40.01 |
Typical Hold Time | 43 Days | 75 Days |
Enterprise Value | $83.51M | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
INO trades at $1.15, down 0.43% on the day, with a bearish technical signal from moving averages and oscillators. The company shows consistent quarterly earnings beats but operates at significant losses with a -130,000% net income margin and negative cash flow. Key catalyst is the FDA's October 30, 2026 PDUFA date for INO-3107, with analyst consensus leaning bullish at a $2.75 price target.
The investment case hinges on FDA approval of INO-3107, offering substantial upside from current levels. However, persistent cash burn, minimal revenue, and high valuation multiples relative to sales pose significant risks. Investors face binary outcomes driven by regulatory decisions and commercialization execution.
XLRE, the State Street Real Estate Select Sector SPDR ETF, trades at $41.61, up 2.56% on the day, but technical indicators signal a bearish trend with moving averages and overall momentum favoring sellers. The ETF offers a low expense ratio of 0.08% and focuses on 30 U.S. large-cap real estate holdings, providing concentrated exposure to the domestic market. Recent news highlights comparisons with global real estate ETFs and discussions on value amid rising bond yields.
The outlook for XLRE is cautious due to bearish technicals and sensitivity to interest rate fluctuations, though its low cost and U.S. focus present a streamlined real estate investment option. Key risks include macroeconomic pressures from potential rate hikes and sector underperformance relative to digital infrastructure themes, requiring careful monitoring of Fed policy and real estate market dynamics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Inovio Pharmaceuticals Inc
Inovio Pharmaceuticals Inc is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.
Read more on INO →About State Street Real Estate Select Sector SPDR ETF
XLRE tracks the Real Estate Select Sector Index, providing exposure to S&P 500 real estate companies. It focuses on equity REITs across residential, industrial, and healthcare sub-sectors, with top holdings like Welltower, Prologis, and American Tower.
Read more on XLRE →
